2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

4:30PM-6:00PM: Abstract Number: 1937

Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis

4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

4:30PM-6:00PM: Abstract Number: 1905

Lower Education Level Is Associated with Higher Risk of Developing Rheumatoid Arthritis

4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

4:30PM-6:00PM: Abstract Number: 1896

Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling

4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

4:30PM-6:00PM: Abstract Number: 1913

Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis

4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

4:30PM-6:00PM: Abstract Number: 1895

Marked Immune Cell Subset Changes in Refractory Lupus Patients in a Phase I Trial of Allogenic Mesenchymal Stem Cells

4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

4:30PM-6:00PM: Abstract Number: 1934

microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis

4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

4:30PM-6:00PM: Abstract Number: 1924

Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial

4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

4:30PM-6:00PM: Abstract Number: 1903

Molecular Analysis of a Skin Equivalent Tissue Culture Model System of Systemic Sclerosis Using RNA Sequencing, Epigenetic Assays, Histology, and Immunoassays

4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

4:30PM-6:00PM: Abstract Number: 1935

Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate

4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

4:30PM-6:00PM: Abstract Number: 1916

Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy

4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

4:30PM-6:00PM: Abstract Number: 1904

Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases

4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

4:30PM-6:00PM: Abstract Number: 1902

Pathogenic and Therapeutic Modulation of Activating Epigenetic Memory at a Novel Enhancer for TGFβ2 in Systemic Sclerosis

4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

4:30PM-6:00PM: Abstract Number: 1928

Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis

4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

4:30PM-6:00PM: Abstract Number: 1957

Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes

4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957)

4:30PM-6:00PM: Abstract Number: 1917

Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients

4M103 ACR Abstract: Pain Mechanisms–Basic & Clinical Science (1917–1922)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].